Menu Search
Equities

Anhui Huaheng Biotechnology Co Ltd

688639:SHH

Anhui Huaheng Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)38.86
  • Today's Change1.02 / 2.70%
  • Shares traded10.39m
  • 1 Year change-50.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform7
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 4 analysts offering 12 month price targets for Anhui Huaheng Biotechnology Co Ltd have a median target of 69.45, with a high estimate of 96.55 and a low estimate of 40.82. The median estimate represents a 78.72% increase from the last price of 38.86.
High148.5%96.55
Med78.7%69.45
Low5.0%40.82

Dividends in CNY

In 2023, Anhui Huaheng Biotechnology Co Ltd reported a dividend of 0.62 CNY, which represents a 45.00% increase over last year. The 2 analysts covering the company expect dividends of 0.56 CNY for the upcoming fiscal year, a decrease of 9.46%.
Div growth (TTM)45.00%
More ▼

Earnings history & estimates in CNY

On Oct 28, 2024, Anhui Huaheng Biotechnology Co Ltd reported 3rd quarter 2024 earnings of 0.09 per share.
The next earnings announcement is expected on Feb 27, 2025.
Average growth rate-16.56%
Anhui Huaheng Biotechnology Co Ltd reported annual 2023 earnings of 1.96 per share on Feb 23, 2024.
Average growth rate+56.53%
More ▼

Revenue history & estimates in CNY

Anhui Huaheng Biotechnology Co Ltd had 3rd quarter 2024 revenues of 522.81m. This missed the 932.67m estimate of the one analyst following the company. This was 30.62% above the prior year's 3rd quarter results.
Average growth rate+0.81%
Anhui Huaheng Biotechnology Co Ltd had revenues for the full year 2023 of 1.94bn. This was 36.63% above the prior year's results.
Average growth rate+42.66%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.